MedTrace Logo

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

NCT02607215 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2022-04-20

No results posted yet for this study

Summary

Platinum Retreated in Patients with Platinum Sensitive mTNBC

Conditions

Interventions

DRUG

Vinorelbine

25 mg/m2, D1, D8

DRUG

DDP

75 mg/m2, D1

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xichun Hu, MD, PhD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02607215 on ClinicalTrials.gov